Physician profile
James S Sim
NPI 1578678405
$3,956.18
in general payments reported to CMS, 2019-2025
30 companies · $786 in 2025
The $786 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $468 · 2021: $666 · 2022: $573 · 2023: $322 · 2024: $642 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $475.10 | 2019-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $435.56 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $393.09 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Mallinckrodt Hospital Products INC. | $377.79 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $276.84 | 2019-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $275.24 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $218.89 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $185.89 | 2019-2021 | |
| Medtronic, INC. | $167.76 | 2021-2023 | Ellipsys Vascular Access System |
| Vifor Pharma, INC. | $116.49 | 2022-2025 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $105.38 | 2019-2024 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $97.08 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $86.24 | 2019-2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $86.23 | 2019-2025 | Rayaldee |
| Daiichi Sankyo INC. | $80.31 | 2020-2024 | Injectafer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $73.21 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $70.12 | 2022-2024 | Purified Cortrophin Gel |
| Genzyme Corporation | $59.39 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $59.05 | 2022 | |
| Novo Nordisk INC | $58.30 | 2024-2025 | Rivfloza, Rybelsus, Ozempic |
| Ultragenyx Pharmaceutical INC. | $46.75 | 2019-2021 | |
| Horizon Therapeutics Plc | $39.83 | 2023 | Krystexxa |
| Veloxis Pharmaceuticals, INC. | $34.57 | 2020 | |
| Mallinckrodt Enterprises LLC | $32.80 | 2019 | |
| Hikma Pharmaceuticals USA | $22.80 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.86 | 2025 | Tryvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.09 | 2025 | Jardiance |
| Ardelyx, INC. | $15.85 | 2025 | Ibsrela |
| Cormedix INC. | $15.18 | 2024 | Defencath |
| Strongbridge US INC. | $14.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.